Tussilagone attenuates atherosclerosis through inhibiting MAPKs-mediated inflammation in macrophages
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.110066 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Sirui Shen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325035, China; Chemical Biology Research Cen…. Hauptthemen laut MEDLINE: Atherosclerosis, Plaque, Atherosclerotic. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Atherosclerosis is a common chronic inflammatory disease. Recent studies have highlighted the key role of macrophages and inflammation in process of atherosclerotic lesion formation. A natural product, tussilagone (TUS), has previously exhibited anti-inflammatory activities in other diseases. In this study, we explored the potential effects and mechanisms of TUS on the inflammatory atherosclerosis. Atherosclerosis was induced in ApoE-/- mice by feeding them with a high-fat diet (HFD) for 8 weeks, followed by administration of TUS (10, 20 mg ·kg-1·d-1, i.g.) for 8 weeks. We demonstrated that TUS alleviated inflammatory response and reduced atherosclerotic plaque areas in HFD-fed ApoE-/- mice. Pro-inflammatory factor and adhesion factors were inhibited by TUS treatment. In vitro, TUS suppressed foam cell formation and oxLDL-induced inflammatory response in MPMs. RNA-sequencing analysis indicated that MAPK pathway was related to the anti-inflammation and anti-atherosclerosis effects of TUS. We further confirmed that TUS inhibited MAPKs phosphorylation in plaque lesion of aortas and cultured macrophages. MAPK inhibition blocked oxLDL-induced inflammatory response and prevented the innately pharmacological effects of TUS. Our findings present a mechanistic explanation for the pharmacological effect of TUS against atherosclerosis and indicate TUS as a potentially therapeutic candidate for atherosclerosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325035, China; Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, We…
- Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China.
- Department of Cardiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325035, China.
- Department of Cardiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325035, China. Electronic address: susiehzq@126.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Shen, S., Huang, Z., Lin, L., Fang, Z., Li, W., Luo, W., Wu, G., Huang, Z., & Liang, G. (2023). Tussilagone attenuates atherosclerosis through inhibiting MAPKs-mediated inflammation in macrophages. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110066
Vancouver
Shen S, Huang Z, Lin L, Fang Z, Li W, Luo W, et al. Tussilagone attenuates atherosclerosis through inhibiting MAPKs-mediated inflammation in macrophages. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110066
BibTeX
@article{Shen2023,
author = {Shen, Sirui and Huang, Zhuqi and Lin, Liming and Fang, Zimin and Li, Weixin and Luo, Wu and Wu, Gaojun and Huang, Zhouqing and Liang, Guang},
title = {Tussilagone attenuates atherosclerosis through inhibiting MAPKs-mediated inflammation in macrophages},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.110066}
}
EUVIMED